Aug 19, 2026 · 8 min
Moderna’s cancer bet revives its post-COVID story
Moderna Soars, SK Hynix Jumps, Estee Lauder Gains
The episode shows how clinical progress, shareholder pressure, and corporate restructuring are reshaping three very different market narratives.
- 1Moderna’s successful mRNA-based cancer therapy trial sparked a record stock rise and revived its post-COVID growth case.
- 2SK Hynix turned to a major share buyback program as a response to retail investor pressure.
- 3Estée Lauder posted its biggest gain in nearly 15 years after strong revenue and a restructuring plan cutting 10,000 positions.
Don't miss
Moderna’s record stock rise after a successful mRNA-based cancer therapy trial emerges as the episode’s clearest market-moving moment.
The brief
Carol Massar and Emily Griffeo bring in Christine Keynote from the Bloomberg Markets Live blog to examine the day’s most consequential stock moves.
Moderna’s record rise followed a successful trial for an mRNA-based cancer therapy, reviving the company’s prospects after its COVID-19 chapter.
The discussion places Moderna’s move alongside hardware inflation and the AI trade, showing how company-specific news intersects with broader market themes.
SK Hynix is highlighted for a major share buyback designed to appease retail investors, while Estée Lauder posts its biggest gain in nearly 15 years.
Estée Lauder’s turnaround rests on strong fourth-quarter revenue and a restructuring plan that includes cutting 10,000 positions.
What was said on this episode
11 statements · 7 positive · 2 negative · 1 mixed · 1 neutral
Moderna stock rose 177%, marking a record increase.
“we got 177% increase on that stock ticker MRNA by the way. That is a record rise essentially.”
Listen at 1:03
Moderna added $44 billion in market value.
“It added $44 billion in value.”
Listen at 1:14
Moderna’s stock jump caused short sellers $5.5 billion in losses.
“that jump suddenly delivered a five and a half billion dollar loss to any short seller.”
Listen at 1:20
Moderna’s cancer-therapy trial was successful and promising.
“a very successful trial, very promising.”
Listen at 1:38
The trial was the first positive final-stage trial for an mRNA cancer therapy.
“it's the first positive final stage trial for any MRNA based cancer therapy.”
Listen at 1:41
SK Hynix stock declined 50% over two months.
“over the past two months, we've seen the stock really, like, turn lower 50% decline over the past two months.”
Listen at 2:54
SK Hynix announced a $29 billion share buyback plan.
“they did announce plans for a $29 billion share buyback.”
Listen at 3:06
The persistence of AI hardware inflation is uncertain.
“how much of that kind of hardware inflation is going to persist”
Listen at 3:38
Estée Lauder stock gained 16%, its largest increase in nearly 15 years.
“a 16% gain. That's the biggest gain in almost 15 years.”
Listen at 4:06
Estée Lauder reported fourth-quarter revenue above estimates and 5% organic sales growth.
“good set of results. Fourth quarter revenue beating estimates organic sales of 5%.”
Listen at 4:11
Estée Lauder’s restructuring appears pivotal to its turnaround.
“it seems pivotal for the company. Right. It's been trying to turn itself around for a couple of years now.”
Listen at 4:28
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
mRNA-based cancer therapy
The Estée Lauder Companies Inc.Listen to the full episode and explore every guest, topic, and moment on PodLume.